Timing to Minimally Invasive Surgery After Neoadjuvant Chemoradiotherapy for Rectal Cancer: a Multicenter Randomised Controlled Trial
Phase: NA
Conditions: Rectal Cancer
Sponsor: Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria

R;QOPWBQOPWBQWBPP










0 

  

 

   
	
	   0  
 



0$$

0=1<:;B5<:;B2<B2;;
, <B2;;2<:;B
:=>@?CB<






"(*('+ %%,(//#
1$"$(/',('$(  +* **$"(	(+)$,%/% ++'*$/

,%.
3


$(*$(*/
1$"$(/',('$(  +* **$"(	(+)$,%/% ++'*$/

,%.

V3.2018_2018_28_11 
INDEX 
1. 
BACKGROUND AND RATIONALE OF THE STUDY 
1 
2. 
PURPOSE 
2 
3. 
STUDY DESIGN 
2 
3.1. 
STUDY TYPE 
2 
3.2. 
PRIMARY ENDPOINT 
2 
3.3. 
SECONDARY ENDPOINTS 
2 
4. 
ELIGIBILITY 
2 
4.1. 
INCLUSION CRITERIA 
2 
4.2. 
EXCLUSION CRITERIA 
3 
4.3. 
STUDY POPULATION 
3 
4.3.1. 
RECRUITMENT OF PATIENTS 
3 
4.3.2. 
INFORMED CONSENT 
4 
4.3.3. 
LOSS OF CAPACITY FOLLOWING INFORMED CONSENT 
4 
4.3.4. 
SITE ELIGIBILITY 
4 
4.4. 
RANDOMIZATION 
5 
4.4.1. 
PROCESS OF RANDOMIZATION 
5 
4.4.2. 
ARM ALLOCATION 
5 
5. 
PREOPERATIVE WORK UP 
6 
5.1. 
BLOOD TEST 
6 
5.2. 
ENDOSCOPY 
6 
5.3. 
CT SCAN 
6 
5.4. 
MRI 
7 
5.5. 
ERUS (ENDOSCOPIC RECTAL ULTRASOUND) 
7 
6. 
NEOADJUVANT TREATMENT 
7 
6.1. 
CHEMORADIATION THERAPY 
7 
6.2. 
RESTAGING AND TREATMENT-EFFICACY ASSESSMENT AFTER NEOADJUVANT THERAPY 
8 
7. 
SURGERY 
9 
7.1. 
ROBOTIC SURGERY 
9 
7.2. 
STANDARD LAPAROSCOPIC SURGERY 
10 
7.3. 
ROBOTIC TATME (OR TAMIS OR ROBOTIC TRANSANAL SURGERY (RTS)) 
10 
7.4. 
OPERATIVE ASSESSMENT 
10 
8. 
PATHOLOGY 
10 
9. 
POST-OPERATIVE CARE AND FOLLOW UP 
11 
9.1. 
POST-OPERATIVE REPORT 
11 
9.2. 
FOLLOW UP REPORT 
12 
9.3. 
DEATH 
12 
10. 
SAFETY REPORTING 
12 
10.1. 
REPORTING OF SERIOUS ADVERSE EVENTS (SAE) 
12 
10.1.1. 
DEFINITIONS 
12 

V3.2018_2018_28_11 
10.2. 
REPORTING PROCEDURE 
13 
10.2.1. 
NON-SERIOUS ADVERSE EVENTS AND/OR NON-SERIOUS ADVERSE DRUG REACTIONS 
13 
10.2.2. 
SERIOUS ADVERSE EVENTS OR SERIOUS ADVERSE DRUG REACTIONS 
13 
10.2.3. 
EXAMPLES OF SAES THAT DO NOT NEED TO BE REPORTED 
13 
10.3. 
REPORTING OF COMPLICATIONS 
14 
10.4. 
RESPONSIBILITIES FOR SAFETY REPORTING 
15 
11. 
QUALITY OF LIFE ASSESSMENT 
15 
12. 
END OF THE STUDY 
15 
13. 
COSTS EVALUATION 
16 
13.1. 
TRIAL INSURANCE 
16 
14. 
STATISTICAL EVALUATION 
16 
14.1. 
SAMPLE SIZE 
16 
14.2. 
STATISTICAL ANALYSIS 
17 
15. 
ETHICAL CONSIDERATIONS, CONFIDENTIALITY AND QUALITY ASSURANCE 
17 
15.1. 
ETHICAL CONSIDERATIONS AND PATIENT PROTECTION 
17 
15.2. 
CONFIDENTIALITY: SUBJECT IDENTIFICATION – PERSONAL DATA PROTECTION 
17 
16. 
PUBLICATION POLICY 
18 
17. 
REFERENCES 
19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

V3.2018_2018_28_11 
 
1 
MULTICENTER RANDOMIZED CONTROLLED TRIAL 
(TiMiSNAR) 
 
 
TIMING TO MINIMALLY INVASIVE SURGERY AFTER NEOADJUVANT CHEMORADIOTHERAPY 
FOR RECTAL CANCER: A MULTICENTER RANDOMIZED CONTROLLED TRIAL 
1. BACKGROUND AND RATIONALE OF THE STUDY 
 
Chemoradiotherapy is a well-known risk reducing treatment of local recurrence in the 
treatment of rectal cancer, followed by total mesorectal excision (TME). In low rectal tumors, 
surgery alone has the 30% overall survival and a local recurrence rate of about 55-65%, with a 
disease-free survival of 30%-35% [1]. Preoperative administration of fluorouracil-based 
chemotherapy improved local recurrence rates to 7% [2]. The optimal timing of surgery in 
relation to chemoradiation is still controversial. Retrospective analysis has demonstrated in the 
recent decades that the regression of adenocarcinoma can be slow and not complete until after 
several months [3]. More recently, increasing pCR rates have been demonstrated to be 
correlated with longer time interval [4] [5] [6]. Conversely, several reports have shown no 
impact of the interval after chemoradiation on pCR and technical performance [7] [8]. In the 
Lyon trial the rate of pCR or near pCR increased from 10.3% to 26% [9] and in retrospective 
studies the increase rate was about 23%-30%. These results may be explained on the 
relationship between radiation therapy and tumor regression: DNA damage occurs during 
irradiation, but cellular lysis occurs within the next weeks [10]. A recent pilot study on 
comparison of resonance imaging and histopathological responses at two times, has suggested 
that volume reduction and down-staging occur between week 9 and week 14 after neoadjuvant 
treatment, with a 23% pCR rate at longer time [11]. In the Stockholm III trial, a significantly 
lower frequency of postoperative complications was reported, even though not described in 
the other studies where morbidity and complications were the same. All of these studies, 
however, presented some biases, such as absence of randomization, the choice of surgical 
timing made arguably by the surgeon, tumor size and response to RCT, different cut-off period 
and a limited number of recruited patients, that may have negatively or positively influenced 
these results [12] [13]. Delaying surgery with the aim to detect excellent responders for organ 
preservation, eventually, may be legitimate, even though the start of adjuvant therapy, whose 
advantage in pretreated rectal cancer patients is still controversial, would be delayed, and this 
may negatively affect survival [14] [15]. A recent meta-analysis on thirteen reports has been 
published, showing rates of 14% and 20% in the shorter and longer group, respectively. This 
meta-analysis has some biases: the pCR correlation with surgical delay could not be adjusted in 
a multivariate analysis with other clinico-pathological variables, the outcome (DFS and OS) of 
pCR, even if likely better than those without pCR as literature demonstrates, could not be 
directly assessed due to lack of individual patient data, the number of patients operated on in 
the delayed group could have been chosen using a surgical decision, different time intervals 
were grouped all together, no randomized trial were included in the meta-analysis, and the 
relevance of the reports included in was assessed by NOS scale, that is quite arbitrary, several 
reports on observation, demonstrating a higher percentage of pCR, were not included, but it is 
quite relevant to consider also these studies. 
 

V3.2018_2018_28_11 
 
2 
2. PURPOSE 
 
To demonstrate if delayed timing of surgery after neoadjuvant chemoradiotherapy actually 
affects pCR and reflects on DFS and OS rather than standard timing. This prospective trial will 
take place at SS Antonio e Biagio e Cesare Arrigo Hospital in Alessandria. 
3. STUDY DESIGN 
 
3.1. Study Type 
 
The trial is a multicenter, prospective, randomized controlled, unblinded, parallel-group 
trial comparing standard and delayed surgery after neoadjuvant chemoradiotherapy for the 
curative treatment of rectal cancer. Three-hundred and forty patients will be randomized 
on an equal basis to either robotic-assisted/standard laparoscopic rectal cancer surgery 
after 8 weeks or robotic-assisted/standard laparoscopic rectal cancer surgery after 12 
weeks. Eight weeks are the current standard interval to surgery after neodjuvant treatment, 
while 12 weeks represent the “minimum” longer time interval to determine further tumor 
modifications and the “a priori” choice to avoid hypothetic surgical detrimental effect 
(postoperative complications related to radiation therapy). The recruiting interval will be of 
5 years and the follow-up period will end 5 years after the last patient is randomized. 
 
3.2. Primary Endpoint 
 
• pCR 
 
3.3. Secondary Endpoints 
 
• DFS 
• OS 
• postoperative complications (Clavien-Dindo classification) 
• reintervention 
• late complications (Clavien-Dindo classification) 
• radiation toxicity 
• chemotherapy toxicity 
• QoL 
• Functional status 
4. ELIGIBILITY 
 
4.1. Inclusion Criteria 
 
• Age >18 years 
• cT3/4N0/+M0 confirmed on CT-scan, MRI (stratification for T3a-b-c-d) 
• Tumor starting from the distal or medium rectum (even those crossing the peritoneal 
reflection at distal margin, within 15 cm from the anal margin) 

V3.2018_2018_28_11 
 
3 
• Histologically-proven adenocarcinoma of the rectum 
• Eligible for a resective surgery with TME (low anterior resection, intersphyncteric 
resection, abdominoperineal resection) 
• Eligible for resection by minimally-invasive surgery (standard or robotic-assisted 
laparoscopic procedure, all robotic systems will be accepted) 
• Eligible for chemoradiation treatment 
• Able to give written informed consent 
• Capable of completing required questionnaires at time of consent (provided 
questionnaires are available in a language spoke fluently by the participant) 
 
4.2. Exclusion Criteria 
 
• Metastatic disease 
• Squamous carcinoma of the anal canal 
• Synchronous colorectal tumors requiring multi-segment surgical resection (n.b. a benign 
lesion within the resection field in addition to the main cancer would not exclude a 
patient) 
• History of psychiatric or addictive disorder or other medical condition that, in the 
opinion of the investigator, would preclude the patient from meeting the trial 
requirements 
• Pregnancy 
• Unable to complete neoadjuvant treatment 
• Unable to give free informed consent 
• Previous radiation treatment on the pelvis 
• Inflammatory bowel disease 
• Hereditary colorectal disease 
• Previous tumors other than non-melanoma skin cancer, papillary or follicular thyroid 
cancer 
• Participation in another rectal cancer clinical trial relating to the topic of this trial 
 
4.3. Study Population 
 
Patients will be identified after endoscopy and screened for inclusion into the study once 
referred to the colorectal surgeon. 
 
4.3.1. Recruitment of Patients 
 
A total of 340 patients, 170 in each arm, will be enrolled in the trial. In arm A, surgery 
will be performed after 8 weeks; in arm B, surgery will be performed after 12 weeks. 
(See Table 1). Eligibility of participants should be established prior to start neoadjuvant 
therapy. 
 
 
 
 
 

V3.2018_2018_28_11 
 
4 
 
 
 
4.3.2. Informed Consent 
 
Patients will be approached for possible recruitment following diagnosis and 
radiological staging (see section 6), provided they fulfil the inclusion/exclusion criteria 
(see section 5.1 and 5.2). Patients will be provided with verbal and written details. A 
verbal explanation of the trial will be provided by a medically qualified member of the 
healthcare team for the patient to consider. 
Patients will be given the opportunity to discuss the trial with their family and 
healthcare professionals before they are asked whether they would be willing to take 
part in the trial. Patients will be allowed 24 hours as a minimum and one week as a 
maximum, to consider their participation in the trial. Patient can refuse to participate 
in the trial without giving any reasons. 
Patients who accept to participate in, will then be formally assessed for eligibility and 
invited to provide informed, written consent (see appendix 1) for their participation in 
the trial, including explicit consent for the transfer of a copy of their signed consent 
form to the Coordinator Center (CC). 
Informed consent may be obtained by the Principal Investigator (PI) or another 
clinically qualified member of each participating trial center, indicated by the Principal 
Investigator to take informed consent. 
A copy of the signed consent form will be given to the patient. 
Patients will remain free to withdraw from the trial at any time by revoking consent 
without giving reasons and without prejudicing any further treatment. 
 
4.3.3. Loss of Capacity Following Informed Consent 
 
Loss of mental capacity of a patient after giving informed consent for the trial is 
expected to be a rare occurrence. In the event of incapacity, patients will not receive 
any further trial-specific interventions, without prejudicing any further treatment. 
 
4.3.4. Site Eligibility 
 
The trial is a multicenter collaboration, involving all those centers able to provide the 
standard of cure for locally advanced rectal cancer. All the involved centers have to 
respect the following criteria: 
 
• Site able to perform robotic-assisted and standard laparoscopic rectal cancer 
surgery and TaTME (transanal total mesorectal excision) 
• Site able to provide a preoperative work up according to the work up criteria 
specified in this trial (see section 6) 
Table 1 
STANDARD INTERVAL TIME ARM 
DELAYED INTERVAL TIME ARM 
170 pts 
170 pts 
surgery will be performed after 8 weeks 
(non-extended timing) 
surgery will be performed after 12 weeks 
(extended timing) 

V3.2018_2018_28_11 
 
5 
• Site able to provide standard neoadjuvant treatment, both chemo and radiation 
therapy, according to the criteria specified in this trial (see section 7.1) 
• Predicted capability to recruit a minimum of 15 patients per year to the trial. 
 
4.4. Randomization 
 
Randomization should take place as soon as possible after consent is obtained and after 
patients have completed their baseline patient reported questionnaires. Patient consent and 
randomization must take place as close to the date of start of the neoadjuvant treatment as 
possible and must be no more than 30 days prior to planned treatment. 
 
4.4.1. Process of Randomization 
 
Following confirmation of written informed consent and eligibility, patients will be 
randomized into the trial by an authorized member of the staff at each trial center. 
Randomization will be performed centrally by data managers, using the software 
specified in the next section (4.4.2). Randomization form have to be sent via email 
completed in all the specified fields. It will be returned with the indication of the time 
interval by email, as well. The following information will be required at randomization: 
 
• Patient details, including initials, height, weight, gender and date of birth 
• Date of diagnosis 
• Pre-operative investigations performed 
• Planned operation (anterior resection/intersphyncteric resection/APR) 
• Name and code of the trial center 
• Name of the person making the randomization 
• Name and code of the coordinator of the trial center 
• Confirmation of eligibility 
• Confirmation of written informed consent and date obtained 
• Date of randomization 
 
4.4.2. Arm Allocation 
 
Patients will be randomized on a 1:1 basis to receive minimally-invasive rectal cancer 
surgery 8 or 12 weeks after neoadjuvant treatment and will be allocated a unique 
trial number. A computer- generated software with block randomization criteria will 
be used to ensure treatment groups are well-balanced for the following patient 
characteristics, details of which will be required for randomization (see appendix 2): 
 
• Intended surgical technique (robotic/laparoscopic/transanal) 
• Intended RT with or without boost 
 
 
 
 
 

V3.2018_2018_28_11 
 
6 
5. PREOPERATIVE WORK UP 
 
Preoperative investigation and preparation will be as per institutional protocol (see appendix 3 
–  DVA 19 Colorectal cancer Rev. 05 18/02/2016, section 5). In summary, blood test, endoscopy, 
CT scan and MRI are compulsory exams, endoscopic rectal ultrasound is required but not 
compulsory and only for tumors localized within 10 cm from the anal verge. Physical 
examination and digital rectal exploration should precede all instrumental examinations. 
 
5.1. Blood Test 
 
Blood test is mandatory and should include the following markers: 
 
• Complete cell blood count (CBC) 
• Serum level of: 
o Creatinine 
o alanine aminotransferase 
o aspartate aminotransferase 
o Gamma glutamiltransferase 
o Bilirubin 
o Alkaline phosphatase 
o Pseudocholinesterase 
o Prothrombin Time (PT) 
o Partial thromboplastin time (activated) (PTT or aPTT) 
o Antithrombin III 
o Fibrinogen 
o Albumin 
o Total protein count 
o Sodium, Calcium, Potassium, Clorum, Phosphorus, Magnesium 
• HCV, HBV test 
• Carcinoembryonic antigen level (CEA) 
• Carbohydrate antigen 125 (Ca 125) 
 
5.2. Endoscopy 
 
A complete colonoscopy with biopsies is mandatory. In case of stenotic tumor or low patient’s 
compliance to perform a complete colonoscopy, a rectoscopy with biopsies is required, 
completed by CT Colonography. At least 9 biopsies (3 anterior, 3 lateral, 3 posterior 
circumferentially) are required for a complete and more precise pathological report, including 
immunohistochemical and biological features. All trial centers have to send the endoscopic 
report to the coordinator center. 
 
5.3. CT Scan 
 
Thoraco-abdominal CT scan with and without contrast medium is required for staging of 
disseminated disease, if any. The presence of diffuse disease (lung, liver, extraregional lymph 
nodal disease) is an exclusion criterion (see section 5.2). CT Colonography is performed in case 

V3.2018_2018_28_11 
 
7 
of stenotic tumors or low patient’s compliance to the endoscopic exam. All trial centers have 
to send the CT scan report to the coordinator center. 
 
5.4. MRI 
 
Pelvic MRI is mandatory and the technique of first choice for both primary staging and restaging 
of rectal cancer, according to the recommendations from the 2016 European Society of 
Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting [16]; MRI is the most 
accurate test to define locoregional clinical staging. By detecting extramural vascular invasion 
(EMVI), and determining the T substage and circumferential resection margin (CRM), MRI can 
also predict the risks of local recurrence and synchronous/metachronous distant metastases. 
Another important addition to the 2012 guidelines is a recommendation for structured 
reporting; European Society of Gastrointestinal and Abdominal Radiology (ESGAR) has recently 
presented an alternative template (both for primary staging and for restaging after neoadjuvant 
treatment) based on the specific recommendations arising from 2016 updated consensus 
meeting. Studies have shown that implementation of structured report templates can improve 
the quality of MRI reporting for rectal cancer staging compared to free-text formats, and leads 
to higher satisfaction levels from referring surgeons [17] [18]. Accordingly, structured reporting 
is now recommended by the panel unanimously and it will be a mandatory item for this trial 
(see appendix 4). No MRI reports without this template will be accepted. All trial centers have 
to send the structured template to the coordinator center. 
High quality MRI allows further subclassification of cT3, which is recommended by ESMO 
guidelines and it is useful in stratifying and selecting patients with indication to neoadjuvant 
treatment before surgery (table 1) [19]. 
 
Table 1. Subclassification of T3 rectal cancer 
 
 
Depth of invasion beyond the muscularis 
propria (mm) 
T3a 
<1 
T3b 
1-5 
T3c 
6-15 
T3d 
>15 
 
5.5. ERUS (Endoscopic rectal ultrasound) 
 
ERUS has indication in earliest tumor (T1-T2), which can be selected for transanal endoscopic 
microsurgery (TEM); ERUS provides less value in locally advanced rectal cancer and it may be 
indicated in those patients who refuses undergo MRI or with contraindications. 
6. NEOADJUVANT TREATMENT 
 
6.1. Chemoradiation Therapy 
 
Several phase II studies have indicated the use of concomitant chemotherapy for better efficacy 
from such combination. The studies showed downstaging with pCR of more than 15% after 
preoperative CRT compared with approximately 5% after RT alone [20] [21]. 

V3.2018_2018_28_11 
 
8 
Two recent randomized trials, comparing preoperative RT with CRT, in resectable cases, 
demonstrated that local control is significantly better in the combined modality groups, but 
with no significant gain in OS. The trials do not give an answer to whether the addition of 
chemotherapy mainly works as a radiosensitizer, improving local control, or if it has an effect 
of its own [22] [23]. In the European Organization for Research and Treatment of Cancer 
(EORTC) study, a favorable effect on local control was seen with concomitant chemotherapy, 
even though no conclusive results were demonstrated [24]. The addition of chemotherapy 
resulted in the Locally Advanced Rectal Cancer Study (LARCS) in more sphincter-preserving 
procedures although this was not an end point in the study. 
Concomitant chemotherapy advantages can be summarized as follows: 
• Improved sensitivity to radiation therapy on neoplastic cells 
• Higher systemic control of the disease (micrometastases eradication) 
• Increased complete pathological response and sphincter preservation 
 
The initial trials of trimodality therapy in rectal cancer utilized a fluoropyrimidine bolus (5FU – 
5-fluorouracil) has been recently overcome by continuous infusion of 5FU that improves local 
control, distant metastases and survival. 
Recent data have shown that capecitabine can replace 5FU in chemoradiotherapy with 
equivalent efficacy and comparable toxicity profile, also avoiding the insertion of a central 
venous catheter [25]. 
Concomitant chemotherapy treatment associated to long course radiation therapy with IMRT 
(Intensity Modulated RadioTherapy – 50-54 Gy in 25-28 fractions; an optional boost is 
suggested) consists of Capecitabine 825 mg /m2/ twice daily during radiation therapy. 
When one or more side effects are experienced, a specified form must be completed, if 
neoadjuvant treatment is not completed, informing the patient being excluded from this trial 
(see neoadjuvant exclusion form). 
 
6.2. Restaging and treatment-efficacy assessment after Neoadjuvant Therapy 
 
Assessment of treatment efficacy has principally relied on histopathologic findings on the 
specimen after surgery. Qualitative evaluation of the degree of fibrosis in the pathologic 
specimen can be used to derive a tumor regression grading (TRG) system. Accurate 
preoperative assessment of response to therapy (restaging) may permit to better define the 
final treatment strategies. Morphological MRI evaluation is considered the best available tool 
for locally advanced rectal cancer staging after neoadjuvant treatment, allowing an accurate 
evaluation of the disease extent and of the lymph node involvement. The MERCURY study group 
has developed an MRI-based tumor regression grading (ymrTRG) system by applying the 
principles of histopathological ypTRG [26]. 
Recently, a pilot study from UK has defined two groups of patients divided into favourable vs 
unfavourable responders based on the following three factors: 
 
• ymrT 
• ymrTRG 
• Change in volume 
 
ymrT is based on the interpretation of local extent of persistent tumor signal intensity relative 
to the layers of bowel wall on T2-weighted images. Tumor response is evaluated as either 

V3.2018_2018_28_11 
 
9 
replacement of tumor signal by low signal intensity fibrosis (dark stroma) or the development 
of high signal intensity mucin pools, that are not considered to be tumor. 
ymrTRG is based on principles similar to the pathological ypTRG system described by Dworak 
and subsequently modified by Mandard. 
Change in volume, better defined as percentage volume reduction is calculated multiplying 
tumor length, width and height, using the following formula: 
 
100*{(Volume at baseline) - (Volume post-CRT)}/(Volume at baseline) 
 
Restaging is worked out generally between week 4 and 6 after neoadjuvant treatment (mean 
90 days). Further volume reduction and down staging have been investigated to occur up to 
week 14 after radiation therapy. Time interval to surgery in this trial are 8 weeks and 12 weeks 
after treatment, that are the standard and the expected “minimum” longer time interval to 
determine further tumor modifications. Post-treatment staging for evaluation of 
postneoadjuvant treatment response, eventually, will depend on MRI evaluation at week 7 for 
patients in both the two arms; a MRI evaluation will be repeated at week 11 for patients 
randomized in the delayed arm. 
A Thoraco-abdominal CT-Scan with and without contrast enhancement will be performed at 
week 6 after neoadjuvant surgery, for restaging of potential disseminated disease. 
7. SURGERY 
 
Minimally-invasive mesorectal resection is required: both robotic or standard laparoscopic 
approach or Robotic TaTME will be accepted, in accordance with each surgeon’s usual practice. 
The specifics of each operation will be at the discretion of the operating surgeon (e.g. port-site 
placement, mobilization of the splenic flexure, inferior mesenteric artery/vein division, high 
versus low vascular division etc.), as well as the decision to convert to an open operation. 
Conversion to open operation is defined as the use of a laparotomy wound for any part of the 
mesorectal dissection. All participating centers are allowed and encouraged to use Indocyanine 
Green test (ICG), wherever available, but it is not mandatory. Indocyanine green is a sterile, 
water-soluble protein-binding dye with low toxicity and fast biliary excretion [27]. Dose and 
utilization information have to be sent to the CC. 
 
7.1. Robotic Surgery 
 
Robotic surgery is intended as a surgical technique that utilizes a computer-assisted aid to 
perform surgical procedures. All devices who respects the identification of “computer-
based” or “robot” system are allowed. An operation is intended to be performed by robotic 
technique if TME is carried out by robotic assistance. All other steps of the procedure can 
be performed either by standard laparoscopy or by robotic technique. Participating centers 
with at least 20 Robotic TME performed before starting the trial are allowed to use robotic 
assistance for TME. 
 
 
 
 

V3.2018_2018_28_11 
 
10 
7.2. Standard Laparoscopic Surgery 
 
Either Standard or 3D-laparoscopy are allowed to be performed for TME. Centers have to 
provide documentation of at least 50 laparoscopic procedures performed before starting 
the trial. 
 
 
7.3. Robotic TaTME (or TAMIS or Robotic Transanal Surgery (RTS)) 
 
Robotic transanal surgery (RTS) is a newer approach to rectal dissection whose purpose is 
to overcome the limits of the traditional transabdominal approach, improving accuracy of 
distal dissection and preservation of hypogastric innervation. Although there are few 
published cases in literature, an increasing interest on this new technique has raised, thanks 
to the excellent pathological and acceptable short-term clinical outcomes reported [28] [29] 
[30]. The purpose of this trial is not to value the efficacy of TaTME, which is intended to be 
performed only by those centers with high specialization on robotic surgery, with at least 5 
TaTME procedures performed before starting the trial. 
 
7.4. Operative Assessment 
 
An operative clinical case report (CRF) will be completed and will include the following items 
(see appendix 5): 
 
• Surgeon 
• ASA status 
• Surgical (robotic-assisted/standard laparoscopy/TaTME) 
• Details of previous abdominal operations 
• Type of operation performed (anterior resection/intersphyncteric resection/APR) 
• Duration of operation (docking time, robotic time, total operation time) 
• In case of robotic approach, conversion to laparoscopic or open technique and 
reasons 
• In case of TaTME approach, conversion to either transabdominal robotic or 
laparoscopic or open technique and reasons 
• Any intra-operative complications 
8. PATHOLOGY 
 
Histopathological analysis of the rectal resection specimens is recommended according to 
internationally agreed criteria. 
A complete and correct histopathology report have to include: 
 
• Gross description including site, maximum tumor size, distance from distal and proximal 
resection margins, evidence and site of perforation (if any), plane of surgical excision 
(mesorectal, intramesorectal or muscularis propria for mesorectum and extralevator, 
sphincteric or intrasphincteric/submucosal/perforation for APR only) and distance from 
dentate line (for APR). Hystopathological examination should include a photographic 

V3.2018_2018_28_11 
 
11 
record of the surgical specimen and assessment of TME quality [III, B], which is a strong 
quality control measure. 
• Histology including type and differentiation, local invasion (including depth of extramural 
invasion), margin involvement, proximal and distal cut ends, and distance to the non-
peritonealized circumferential resection margin (CRM) and whether complete (R0) 
resection. If CRM involved then maximal length of involved margin, mode of involvement 
at CRM. All measures have to be in millimeters. A proforma report such as the one by 
the Royal College of Pathologists is recommended (see appendix 6). 
• Any evidence of response to neoadjuvant therapy (Dworak score [31] – see appendix 7) 
• Locoregional spread including lymph nodes1 (number retrieved and number involved), 
lymphatic or extramural vascular invasion, perineural invasion (EMVI, EMLI, PNI), 
presence of tumor deposits (ENE) 
• Tumor budding 
• MSI (N-RAS, B-RAF, K-RAS) investigation 
• Co-existent conditions including ulcerative colitis or Crohn’s disease 
• TNM (v.8, 2013 – see appendix 8) 
 
All participating centers are required to submit the histopathological report to the coordinator 
center with the following patient information: 
 
• Unique trial number 
• Initials 
• Date of birth 
• Local histopathology report number 
9. POST-OPERATIVE CARE AND FOLLOW UP 
 
Post-operative care and follow up will be as per institutional protocol, but patients must be 
reviewed at 30 days, and 6 months post-operatively at a minimum (see appendix 9). Any further 
visits will be according to local standard clinical practice. All patients will be followed up as per 
protocol until 5 years after the last patient has been randomized. 
 
9.1. Post-Operative Report 
 
Data collected will include (see appendix 10): 
 
• Duration of post-operative hospital stay 
• Post-operative complications and severity (any correlated discharge delay must be 
reported) 
• Details of any reoperation required and reason 
• Patient status (alive or dead) 
 
                                                        
1 Although a minimum number of 12 lymph nodes are accordingly sufficient to be examined for a good pathological 
staging, all centers are encouraged to retrieved as more lymph nodes as possible. The more lymph nodes 
examined, the more correct p-staging is achieved. 

V3.2018_2018_28_11 
 
12 
9.2. Follow Up Report 
 
Data collected will include (see appendix 11): 
 
• Detail of any further therapy 
• Details of any local or distant recurrence, including: 
 
o Date of recurrence 
o Site of recurrence 
o Method of diagnosis 
 
• Details of any new primary cancer diagnosis 
• A medical history, physical examination, Karnofsky and toxicity score (if any ongoing 
medical treatment) 
• CT, MRI, PET (if required) report 
• Quality of life questionnaires 
• Blood test as previously specified (see section 6.1) 
 
9.3. Death 
 
All deaths must be recorded on the Notification of Death CRF, complete of date of death 
and cause of death (see appendix 12). 
10. SAFETY REPORTING 
 
10.1. 
Reporting of Serious Adverse Events (SAE) 
 
10.1.1. Definitions 
 
AE: An Adverse Event is defined as any untoward medical occurrence in a patient or 
clinical trial subject administered a medicinal product and which does not necessarily 
have a causal relationship with this treatment. An adverse event can therefore be any 
unfavorable and unintended signs (such as rash or enlarged liver), symptoms (such as 
nausea or chest pain), an abnormal laboratory finding (including blood tests, x-rays or 
scans) or a disease temporarily associated with the use of the protocol treatment, 
whether or not considered related to the investigational medicinal product. 
AR: An Adverse reaction of an investigational medicinal product is any untoward and 
unintended responses to an investigational medicinal product related to any dose 
administered. All adverse events judged by either the reporting investigator or the 
sponsor as having a reasonable causal relationship to a medicinal product qualify as 
adverse reactions. The expression reasonable causal relationship means to convey in 
general that there is evidence or argument to suggest a causal relationship. 
UAR: An Unexpected Adverse Reaction is any adverse reaction, the nature, or severity of 
which is not consistent with the applicable product information (e.g. investigator's 
brochure for an unapproved investigational product or summary of product 
characteristics (SmPC) for an authorised product). When the outcome of the adverse 

V3.2018_2018_28_11 
 
13 
reaction is not consistent with the applicable product information this adverse reaction 
should be considered as unexpected. 
Severity: The term “severe” is often used to describe the intensity (severity) of a specific 
event. This is not the same as “serious,” which is based on patient/event outcome or 
action criteria. 
SAE: A Serious Adverse Event is defined as any undesirable experience occurring to a 
patient, whether or not considered related to the protocol treatment. 
SAR: A Serious Adverse Event (SAE) which is considered related to the protocol treatment 
is defined as a Serious Adverse Reaction. 
An Adverse Event or Adverse Reaction which is considered as serious: 
 
• results in death 
• is life-threatening (i.e. an event in which the subject was at risk of death at the 
time of event; it does not refer to an event which hypothetically might have caused 
death if it were more severe) 
• requires hospitalization or prolongation of existing inpatients´ hospitalization 
• results in persistent or significant disability or incapacity 
• is a congenital anomaly or birth defect 
• results in any other medically important condition (i.e. important adverse 
reactions that are not immediately life threatening or do not result in death or 
hospitalization but may jeopardize the patient or may require intervention to 
prevent one of the other outcomes listed above). 
 
SUSAR: Suspected Unexpected Serious Adverse Reactions 
 
10.2. 
Reporting Procedure 
 
10.2.1. Non-Serious Adverse Events And/Or Non-Serious Adverse Drug Reactions 
 
Adverse Events (AE) and /or Adverse Reactions (AR) must be recorded as indicated in the 
trial. 
 
10.2.2. Serious Adverse Events Or Serious Adverse Drug Reactions 
 
All Serious Adverse Events (SAE) occurring from the time a subject is registered until 30 
days after last trial treatment, must be reported within 24 hours. 
All SAEs that are simply signs and symptoms of the disease being studied do not need to 
be collected, unless more severe than expected for the subject’s condition. 
 
10.2.3. Examples of SAES that Do Not Need to Be Reported 
 
• Medical or surgical procedure (e.g., endoscopy, appendectomy); the condition that 
leads to the procedure is an AE. 
• Situations where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital). 
• Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen. 

V3.2018_2018_28_11 
 
14 
• The disease/disorder being studied, or expected progression, signs, or symptoms of 
the disease/disorder being studied, unless more severe than expected for the 
subject's condition. 
• A hospitalization which was planned before the patient consented for study 
participation and where admission did not take longer than anticipated. 
 
Any SAE that occurs outside of the SAE detection period (after the 30-days period), 
considered to be reasonably related to the investigational treatment or study 
participation, have to be promptly notified. 
This must be done by fax within 24 hours of the initial observation of the event. The 
principal investigator will decide if these events are related to the trial treatment (i.e. 
unrelated, likely related, and not assessable) and the decision will be recorded on the 
Serious Adverse Event form, if necessary with the reasoning of the principal investigator. 
The investigator is obligated to assess the relationship between investigational treatment 
and the occurrence of each AE/SAE. A "reasonable possibility" is meant to convey that 
there are facts/evidence or arguments to suggest a causal relationship, rather than a 
relationship cannot be ruled out. The investigator will use clinical judgement to determine 
the relationship. Alternative causes, such as natural history of the underlying diseases, 
concomitant therapy, other risk factors, and the temporal relationship of the event to the 
investigational product will be considered and investigated. 
For the causality assessment, the following definitions must be used: 
 
Details should be documented on the specified Serious Adverse Event Form (see appendix 
13). 
 
 
10.3. 
Reporting of Complications 
 
Information on all complications will be collected for this trial whether volunteered by the 
patient, discovered by investigator questioning or detected through physical examination, 
laboratory test or other investigation. 
For each complication, the following data will be collected (see appendix 14): 
Relationship to the trial treatment description 
Description 
UNRELATED 
There is no evidence of any causal relationship 
to the protocol treatment 
LIKELY RELATED 
There is (some) evidence to suggest a causal 
relationship to the protocol treatment and 
influence of other factors is unlikely or absent. 
 
NOT ASSESSABLE 
There is insufficient or incomplete evidence to 
make a clinical judgement of the causal 
relationship to the protocol treatment. 

V3.2018_2018_28_11 
 
15 
• Start and end dates of event, if resolved (and times, if known/applicable) 
• Full details of complication in medical terms with a diagnosis (if possible) 
• Action/intervention 
• Outcome 
 
10.4. 
Responsibilities for Safety Reporting 
 
Principal Investigator (i.e. Lead trial clinician at each recruiting site or appropriate clinical 
individual identified in trial delegation log) 
• Checking for complications during admission and follow-up, including judgment in assigning: 
 
o causality i.e. whether an untoward medical event is related (i.e. a complication which 
therefore needs to be reported) or unrelated (i.e. not a complication and therefore 
does not need to be reported) 
o seriousness 
o expectedness 
 
Chief Investigator (or nominated individual in PI’s absence) 
 
• Assign relatedness and expected nature of reported complications/untoward medical 
events where it has not been possible to obtain local assessment 
• Undertake review of Unexpected Serious Complications (USCs) (see section 11.1) 
 
Data Monitoring 
 
A Data and Safety Monitoring Board (DSMB) will monitor the recruitment, the reported adverse 
events and the data quality at least one a year. Arising problems will be discussed with the 
Coordinator Center who will take appropriate measures. Relevant information (including 
relevant safety data) will be included in the study status reports serving as a basis of discussion 
during the group meetings. These reports will be made available to investigators participating 
to the study. (see section 15.3). 
 
11. QUALITY OF LIFE ASSESSMENT 
 
Patients will also be asked to complete the baseline generic health-related QoL and fatigue 
questionnaires (SF-36v2 and MFI-20) and patient reported bladder and sexual function 
questionnaires (I-PSS and IIEF/FSFI) following informed consent and prior to randomization (see 
appendix 15). 
12. END OF THE STUDY 
 
The end of the study is defined as 5 years after the date that the last patient has been randomized 
to the trial. 

V3.2018_2018_28_11 
 
16 
13. COSTS EVALUATION 
 
The present trial is a no profit clinical study and does not require additional costs, i.e. in terms 
of laboratory tests, imaging, surgical treatment, compared to similar cases of standard rectal 
cancer treatment. 
 
13.1. 
Trial Insurance 
 
This is a No-Profit multicenter, prospectically-structured study Trial, in which no 
“experimental” drug or technique will be utilized for the treatment of the specified disease. 
Both robotic and laparoscopic techniques are commonly used in Our Hospital and 
worldwide, respecting the definition of “Good Clinical Practice” (section 2.4 of the MoH’s 
decree of December 17, 2004) and covered by the insurance policy in force in Our Hospital 
and in the other participating centers. 
14. STATISTICAL EVALUATION 
 
14.1. 
Sample Size 
 
The primary endpoint is the pCR rate. Based on the published results from prospective 
studies on delayed time interval or observation only and on retrospective study for 
standard time interval, we assume that the mean rate of pCR in the standard treatment is 
about 15%, while the mean pCR rate in the observation treatment or longer time interval 
is 30%. To determine this difference, 270 patients are required, using a two-group 
continuity corrected c2 test of equal proportions, assuming an a error of 4.9% and a power 
of 80% (MedCalc Version 17.9.7); an interim analysis on efficacy will be performed when 
half of events will be observed. The conservative Haybittle-Peto [32] boundary will be used 
as a stopping guidance in order to perform the final analysis at the significance level of 
4.9%, two sides. Considering results from the pilot study reported on section 1, the 
percentage of unfavourable patients is 20% (favourable MRI tumor regression grade is 
defined as grades 1, 2 and 3; unfavourable MRI regression as grades 4 and 5). In addition, 
a meta-analysis on results from five randomized European clinical trials for locally advanced 
rectal cancer, has confirmed this rate of “poor” responders subgroup, identified by having 
no pCR and no DFS within 2 years [33]. In computing the sample size, we assume that the 
percentage of missing data will be 5%. A total of 340 patients, 170 for each arm, is intended 
to be enrolled, eventually. Patients will be randomized on a 1:1 basis to receive minimally-
invasive rectal cancer surgery 8 or 12 weeks after neoadjuvant treatment and will be 
allocated a unique trial number. A computer-generated software with block randomization 
criteria will be used to ensure treatment groups are well-balanced for the specified patient 
characteristics (see section 5.4.1). All enrolled patients’ data will be registered in a 
prospective electronic database (ACCESS, MICROSOFT OFFICE Professional Plus 2010, 
regular licensed). 
 
 
 

V3.2018_2018_28_11 
 
17 
14.2. 
Statistical Analysis 
 
All efficacy outcomes will be assessed in the intention-to-treat population, which includes 
all enrolled patients who did not violate the eligibility criteria. pCR, OS and DFS will be 
assessed from the time of treatment allocation to local progression, death or disease 
progression. Patients who will not die and will not experience local of distant disease 
progression at the date of study cutoff will be censored at the last available information on 
status. 
Time-to-event data will be analyzed by the Kaplan-Meier method and compared with the 
log-rank test. Cox proportional hazards model will be used to adjust the treatment effect 
for baseline prognostic factors. 
15. ETHICAL CONSIDERATIONS, CONFIDENTIALITY AND QUALITY ASSURANCE 
 
15.1. 
Ethical Considerations and Patient Protection 
 
The PI will ensure that the study will be performed in accordance with either the Declaration 
of Helsinki (Tokyo, Venice, Hong Kong and Somerset West amendments) or the laws and 
regulations of the country, whichever provides the greatest protection of the patient. 
The trial has been written, and the study will be conducted according to the Guidelines for 
Good Clinical Practice. The protocol and its annexes are subject to review and approval by 
the competent Independent Ethics Committee (IEC). 
 
15.2. 
Confidentiality: Subject Identification – Personal Data Protection 
 
All records identifying the subject will be keep confidential and, to the extent permitted by 
the applicable laws and/or regulations, not to be made publicly available. A sequential 
identification number (number of randomization - RND) will be automatically attributed to 
each patient registered in the study, any other personal identity information (name, 
surname, etc.) will not be registered to the Data Center. RND will identify the patient and 
must be included on all CRFs. In order to avoid identification errors, patient initials and date 
of birth will also be reported on the CRFs. 
Any and all patient information or documentation pertaining to a clinical trial, to the extent 
permitting, through a “key” kept anywhere, regardless of whether such key is supplied 
along with the information or documentation or not, must be considered as containing 
sensitive personal data of the patient, and is therefore subjected to the provisions of 
applicable data protection (privacy) regulations. Breach of such regulations may result in 
administrative or even criminal sanctions. 
The informed consent form for treatment must be accompanied by an information sheet 
prepared according to the regulations described above and a separate patient consent form 
indicating that the patient consents to the processing of such data (see appendix 16).   Such 
information must: 
 
• Identify the roles of the holder and processor (appointed by the holder) of the 
patient personal data (also if not directly identifying the patient), as well as the 
purposes of the personal data collection and processing (medical treatment and 
related/unrelated scientific research) 

V3.2018_2018_28_11 
 
18 
• Adequately describe the flows of communication involving them, particularly if third 
parties should become involved 
• Seek patient’s prior and specific consent to such processing. 
 
Patient information or documentation may be considered anonymous, and as such not 
subject to privacy regulations, only when no key whatsoever, permitting the identification 
of the patient, is any longer available. 
Particular attention should therefore be paid (and information/consent materials adapted 
accordingly) whenever patient data are supplied to third parties and may be autonomously 
processed, or biological samples/materials are taken and kept for future research purposes, 
associated or not with the pathology considered in the study. 
The Principal Investigator (Dott. Igor Monsellato) and the Local Principal Investigators of all 
Participating Centers are also responsible for data management, from collection to 
processing, processing and transfer to the data collection or Case report forms (CRFs). 
16. PUBLICATION POLICY 
 
The trial will be registered with an authorized registry, according to the International Committee 
of Medical Journal Editors (ICMJE) Guidelines, prior to the start of recruitment. 
Credit for the main results will be given to all those who have collaborated in the trial, through 
authorship and contributorship. Authorship decisions will be guided by standard requirements 
for authorship relating to submission of manuscripts to medical journals. These state that 
authorship credit should be based only on the following conditions being met 
(http://www.icmje.org): 
 
• Substantial contribution to conception and design, or acquisition of data, or analysis and 
interpretation of data 
• Substantial contribution to drafting the article or revising it critically for important 
intellectual content 
• Substantial contribution to final approval of the version to be published. 
 
Main Investigators, and relevant senior trial staff will be named as authors in any publication, 
subject to journal authorship restrictions. In addition, all collaborators (surgeons and 
pathologists) will be listed as contributors for the main trial publication, giving details of roles in 
planning, conducting and reporting the trial. 
To maintain the scientific integrity of the trial, data will not be released prior to the first 
publication of the analysis of the primary endpoint, either for trial publication or oral 
presentation purposes, without the permission. 
 
 
 
 
 
 

V3.2018_2018_28_11 
 
19 
17. REFERENCES 
 
[1]  M. M. Giraudo G, "Laparoscopic total mesorectal excision-the Turin experience," Recent 
Results Cancer Res, vol. 165, pp. 167-79, 2005.  
[2]  B. H. H. E. e. a. Sauer R, "Preoperative versus postoperative chemoradiotherapy for rectal 
cancer," vol. 351, pp. 1731-40, 2004.  
[3]  G. B, "Optimal time intervals between pre-operative radiotherapy or chemotherapy and 
surgery in rectal cancer?," Front Oncol, vol. 4, p. 50, 2014.  
[4]  S. G. S. E. e. a. Petrelli F, "Increasing the intervl between neoadjuvant chemoradiotherapy 
and surgery in rectal cancer. A meta-analysis of publoshed studies," Ann Surg, vol. 263, pp. 
458-64, 2016.  
[5]  H. T. P. D. e. a. Erlandsson J, "Optimal fractionation of preoperative radiotherapy and timing 
to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, 
non-inferiority trial," vol. 18, pp. 336-46, 2017.  
[6]  B. E. S. S. e. a. Kaytan-Saglam E, "Delayed versus immediate surgery following short-course 
neoadjuvant radiotherapy in resectable (T3N0/N+) rectal cancer," J Cancer Res Clin Oncol, 
vol. 143, no. 8, pp. 1597-1606, 2017.  
[7]  M. L. K. S. e. a. Lefevre JH, "Effect of interval (7 or 11 weeks) between neoadjuvant 
radiochemotherapy and surgery on complete pathologic response in rectal cancer: A 
multicenter, Randomised, Controlled Trial (GRECCAR-6)," vol. 34, no. 31, pp. 3773-81, 2016.  
[8]  E. P. F. S. e. a. Foster JD, "Surgical timing after chemoradiotherapy for rectal cancer, analysis 
of technique (STARRCAT): results of a feasibility multi-centre randomized controlled trial," 
Tech Coloproctol, vol. 20, no. 10, pp. 683-93, 2016.  
[9]  N. C. b. J. e. a. Francois Y, "Influence of the interval between preoperative radiation therapy 
and surgery on downstaging and on the rate of sphyncter-sparing surgery for rectal cancer: 
The Lyon R90-01 randomized trial," J Clin Oncol, vol. 17, p. 2396, 1999.  
[10] B. K, "Timing of surgery following preoperative therapy in rectal cancer: there is no need for 
a prospective randomized trial," Dis Colon Rectum, vol. 55, pp. e31-32, 2012.  
[11] D. B. M. H. e. a. West MA, "Timing of surgery following neoadjuvant chemoradiotherapy in 
locally advanced rectal cancer - A comparison of magnetic resonance imaging at two time 
points and histopathological responses," EJSO, vol. 42, pp. 1350-58, 2016.  
[12] U. S. H. A. e. a. Tran CL, "Evaluation of safety of increased time interval between neoadjuvant 
chemoradiotherapy and surgery in rectal cancer," Am J Surg, vol. 192, pp. 873-77, 2006.  
[13] P. Y. T. E. Lefevre JH, "Increasing the interval between neoadjuvant chemoradiotherapy and 
surgery in rectal cancer," Ann Surg, vol. 262, p. e116, 2015.  
[14] S. M. B. J. e. a. Breugom AJ, "Adjuvant chemotherapy after preoperative 
(chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and 
meta-analysisof individual patient data," Lancet Oncol, vol. 16, pp. 200-7, 2015.  
[15] G. B. V. V. e. a. Bujko K, "Postoperative chemotherapy in patients with rectal cancer receiving 
preoperative radio(chemo)therapy: A meta-analysis of randomized trials comparing surgery 
+/- a fluoropyrimidine and surgry + a fluoropyrimidine +/- oxaliplatin," Eur J Surg Oncol, vol. 
41, pp. 713-23, 2015.  
[16] L. D. M. M. e. a. Beets-Tan RGH, "Magnetic resonance imaging for clinical management of 
rectal cancer: Updated recommendations from the 2016 European Society of 

V3.2018_2018_28_11 
 
20 
Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting.," Eur Radiol, vol. 
epub ahead of print, 2017.  
[17] S. P. S. N. K. R. Sahni VA, "Structured Report Template on the Quality of MRI Reports for 
Rectal Cancer Staging," AJR Am J Roentgenol, vol. 205, pp. 584-88, 2015.  
[18] S. W. T. W. e. a. Norenberg D, "Structured Reporting of Rectal Magnetic Resonance Imaging 
in Suspected Primary Rectal Cancer: Potential Benefits for Surgical Planning and 
Interdisciplinary Communication," Invest Radiol, vol. 52, pp. 232-39, 2016.  
[19] W. L. T. E. e. a. Glynne-Jones R, "Rectal cancer: ESMO Clinical Practice Guidelines for 
diagnosis, treatment and follow up," Ann Onc, vol. 28, no. Supplement 4, pp. iv22-40, 2017.  
[20] C. A. K. N. e. a. Minsky BD, "Enhancement of radiation-induced downstaging of rectal cancer 
by fluorouracil and high-dose leucov- orin chemotherapy," J Clin Oncol, vol. 10, pp. 79-84, 
1992.  
[21] H. M. R. W. e. a. Mohiuddin M, "Prognostic significance of postchemoradiation stage 
following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers," 
nt J Radiat Oncol Biol Phys, vol. 48, pp. 1075-80, 2000.  
[22] N. M. N.-G. A. e. a. Bujko K, "Long-term results of a randomized trial comparing preoperative 
short-course radiotherapy with preoperative conventionally fractionated chemoradiation for 
rectal cancer," Br J Surg, vol. 93, pp. 1215-23, 2006.  
[23] C. L. C. G. e. a. Bosset JF, "Chemotherapy with preoperative radiotherapy in rectal cancer," N 
Engl J Med, vol. 355, pp. 1114-23, 2006.  
[24] B. J. d. D. M. e. a. Collette L, "Patients with curative resection of cT3-4 rectal cancer after 
preoperative radiotherapy or radiochemotherapy: Does anybody benefit from adjuvant 
fluorouracil-based chemotherapy? A trial of the European Organisation for Research and 
Treatment of Cancer Radiation Oncology Group," J Clin Oncol, vol. 25, pp. 4379-86, 2007.  
[25] W. F. P. S. e. a. Hofheinz RD, "Chemoradiotherapy with capecitabine versus fluorouracil for 
locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial," 
lancet Oncol, vol. 13, no. 6, pp. 579-88, 2012.  
[26] T. F. B. L. e. a. Patel UB, "Magnetic resonance imaging-detected tumor response for locally 
advanced rectal cancer predicts survival outcomes: MERCURY experience," J Clin Oncol, vol. 
29, no. 28, pp. 3753-60, 2011.  
[27] P. F. L. L. e. a. Marano A, "Application of fluorescence in robotic general surgery: review of 
the literature and state of the art," World J Surg, vol. 37, no. 12, pp. 2800-11, 2013.  
[28] N. G. P. H. e. a. Atallah S, "Robotic-assisted transanal surgery for total mesorectal excision 
(RATS-TME): a description of a novel surgical approach with video demonstration," Tech 
Coloproctol, vol. 17, pp. 441-47, 2013.  
[29] A. M. D.-A. T. L. S. Atallah S, "Transanal minimally invasive surgery (TAMIS): applications 
beyond local excision," Tech Coloproctol, vol. 17, pp. 239-43, 2013.  
[30] A.-R. G. H. L. A. S. Martin-Perez B, "A systematic review of transanal minimally invasive 
surgery (TAMIS) from 2010 to 2013," Tech Coloproctol, vol. 18, no. 9, pp. 775-88, 2014.  
[31] K. L. H. A. Dworak O, "Pathological features of rectal cancer after preoperative 
radiochemotherapy," Int J Colorectal Dis, vol. 12, no. 1, pp. 19-23, 1997.  
[32] H. JL, "repeated assessment of results in clinical trials of cancer treatment.," Be j radiol, pp. 
793-797, 1971.  

V3.2018_2018_28_11 
 
21 
[33] v. S. R. L. G. Valentini V, "Selection of appropriate end-points (pCR vs 2yDFS) for tailoring 
treatments with prediction models in locally advanced rectal cancer," Radiother Oncol, vol. 
114, no. 3, pp. 302-9, 2015.